Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes

Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K. New England Journal of Medicine 2021

Document identifier
CEI-BR-027
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K
Title
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes
Source
New England Journal of Medicine
Year
2021
Volume, issue, pages
385(6):503–515
Digital object identifier
10.1056/NEJMoa2107519
PubMed identifier
34170647
Record type
Journal article
Institute identifier
CEI-BR-027

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: TirzepatideCompound monograph
Trial abstract: SURPASS-2Trial abstract
Synthesis: Tirzepatide compared with semaglutide in type 2 diabetesEvidence synthesis
3 citing documents.

§1.3Subject tags

tirzepatide semaglutide head-to-head SURPASS

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.